Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study
Anticancer Research · 2025
DOI: 10.21873/anticanres.17808 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Anticancer Research, 2025. Verfasst von Akifumi Kuwano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan; akuwnaoh1@aih-net.com. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Quinolines, Bevacizumab.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan; akuwnaoh1@aih-net.com.
- Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan.
- Department of Gastroenterology, Ichinomiyanishi Hospital, Aichi, Japan.
Zitieren
APA
Kuwano, A., Yada, M., Tanaka, K., Hamomoto, T., Kurosaka, K., Suzuki, H., & Motomura, K. (2025). Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study. Anticancer Research. https://doi.org/10.21873/anticanres.17808
Vancouver
Kuwano A, Yada M, Tanaka K, Hamomoto T, Kurosaka K, Suzuki H, et al. Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study. Anticancer Research. 2025. doi:10.21873/anticanres.17808
BibTeX
@article{Kuwano2025,
author = {Kuwano, Akifumi and Yada, Masayoshi and Tanaka, Kosuke and Hamomoto, Taikan and Kurosaka, Kazuki and Suzuki, Hideo and Motomura, Kenta},
title = {Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17808}
}
EUVIMED